Prediction of Antibiotic Efficacy in Cerebral Hemorrhage-Associated Pneumonia Using Inflammatory Hematological Indices: A Retrospective Study

利用炎症血液学指标预测脑出血相关性肺炎的抗生素疗效:一项回顾性研究

阅读:1

Abstract

PURPOSE: The role of inflammatory response in secondary infections following cerebral hemorrhage has attracted considerable attention. We aimed to explore the associations between inflammatory markers and antibiotic efficacy on the cerebral hemorrhage-associated pneumonia. METHODS: We conducted a retrospective study including 200 patients with cerebral hemorrhage-associated pneumonia. In the retrospective study, baseline data, blood cell counts, and C-reactive protein (CRP) were collected. The inflammatory markers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammatory index (SII) were calculated. The difference between the values at admission and at the time of initial efficacy evaluation was denoted by "Δ". These inflammatory markers were examined as potential biomarkers to predict the efficacy of initial antibiotic treatment in finally included patients by univariate analysis and multivariate logistic regression models. RESULTS: In the final analysis, there were 105 cases with effective antibiotic treatment and 95 cases with ineffective antibiotic treatment. At the time of initial efficacy evaluation, there were significant differences in the values of NLR, MLR, PLR, SII, and CRP, P<0.05. Significant differences were also showed in the values of ΔNLR, ΔMLR, and ΔSII, P<0.05. The results of multivariate logistic regression model showed that ΔNLR (OR: 1.260, P=0.016), ΔPLR (OR: 0.985, P=0.008), and CRP (OR: 0.975, P=0.043) at the time of efficacy evaluation were possibly associated with the antibiotic efficacy. CONCLUSION: ΔNLR, ΔPLR, and CRP at the time of efficacy evaluation appear the promising parameters in guiding antibiotic treatment in patients with cerebral hemorrhage-associated pneumonia. However, large-sample, multicenter external validation studies are still needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。